![Halozyme Therapeutics, Inc. logo](/logos/HALO.webp)
Halozyme Therapeutics, Inc.
NASDAQ:HALO
Overview | Financials
Company Name | Halozyme Therapeutics, Inc. |
Symbol | HALO |
Currency | USD |
Price | 59.21 |
Market Cap | 7,500,604,380 |
Dividend Yield | 0% |
52-week-range | 32.83 - 65.53 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. |
Website | https://www.halozyme.com |
An error occurred while fetching data.
About Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD